S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Exopharm Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive EX1 News and Ratings via Email

Sign-up to receive the latest news and ratings for Exopharm and its competitors with MarketBeat's FREE daily newsletter.

About Exopharm

Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing Naïve EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
$4.19 million
Book Value
A$0.12 per share





Next Earnings Date
Not Optionable


Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Exopharm (ASX:EX1) Frequently Asked Questions

What stocks does MarketBeat like better than Exopharm?

Wall Street analysts have given Exopharm a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Exopharm wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Exopharm's key executives?

Exopharm's management team includes the following people:
  • Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D., Company Founder, Technology Co-Founder, MD & Director
  • Dr. Gregor Lichtfuss M.Sc., Co-Founder & Bus. Services Mang.
  • Dr. Christopher Baldwin Ph.D., Deputy CEO & Chief Commercial Officer
  • Ms. Elizabeth McGregor B.A., M.B.A., Company Sec. & Non-Exec. Director

What is Exopharm's stock symbol?

Exopharm trades on the ASX under the ticker symbol "EX1."

How much money does Exopharm make?

Exopharm has a market capitalization of $0.00 and generates $4.19 million in revenue each year.

How many employees does Exopharm have?

Exopharm employs 41 workers across the globe.

What is Exopharm's official website?

The official website for Exopharm is www.exopharm.com.

How can I contact Exopharm?

The company can be reached via phone at 61 3 9111 0026.

This page was last updated on 10/24/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.